US 11,999,990 B2
Method for assaying the activity of spermidine/spermine N1-acetyltransferase
Brian Cheng, Richmond (CA); Rashid Bux, Richmond (CA); and Daniel Sitar, Richmond (CA)
Assigned to BioMark Technologies Inc., Richmond (CA)
Filed by BioMark Technologies Inc., Richmond (CA)
Filed on Aug. 25, 2022, as Appl. No. 17/895,690.
Application 17/895,690 is a continuation of application No. 17/406,956, filed on Aug. 19, 2021, granted, now 11,441,168.
Application 17/406,956 is a continuation of application No. 14/358,695, abandoned, previously published as PCT/CA2012/050828, filed on Nov. 16, 2012.
Claims priority of provisional application 61/560,700, filed on Nov. 16, 2011.
Prior Publication US 2023/0069827 A1, Mar. 9, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/48 (2006.01); G01N 33/574 (2006.01)
CPC C12Q 1/48 (2013.01) [G01N 33/57407 (2013.01)] 8 Claims
OG exemplary drawing
 
1. A method for determining activity of spermine/spermidine N1-acetyltransferase (SSAT) in a mammal, the method comprising:
(a) providing a biological sample from the mammal obtained after an administration of a dose of rimantadine, wherein the biological sample comprises a detectable level of N-acetyl rimantadine; and
(b) quantifying the detectable level of N-acetyl rimantadine in the biological sample, thereby determining SSAT activity in the mammal.